PDCD1 and non-small cell lung carcinoma: Additionally, compared to the combined treatment of PD-1 or PD-L1 inhibitors with chemotherapy +/− anti-angiogenic drugs, AK112 combined with chemotherapy exhibited significant antitumor activity across different patient populations with advanced NSCLC [91].